Business Context and Reporting Period
This Form 8-K Current Report was filed by Oramed Pharmaceuticals Inc. on May 23, 2021. The filing discloses a material corporate governance event: the appointment of a new Chief Financial Officer.
Key Financial Metrics
This filing does not contain financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity metrics. The document focuses exclusively on executive compensation and appointment details.
Material Changes
The primary material change reported is the appointment of David Silberman to serve as Chief Financial Officer, Treasurer, and Secretary, effective July 5, 2021. Mr. Silberman brings prior experience from Teva Pharmaceutical Industries Ltd. and Grant Thornton.
Management Commentary and Compensation
- Employment Terms: Mr. Silberman will be employed by the Company's wholly-owned Israeli subsidiary, Oramed Ltd.
- Base Salary: Gross monthly salary of NIS 37,500.
- Benefits: Includes a company car.
- Variable Compensation: Eligible for bonuses and equity grants, amounts to be determined at the discretion of the Board of Directors and the Compensation Committee.
- Indemnification: The Company expects to enter into a standard indemnification agreement with Mr. Silberman.
Investor Verification Checklist
- Verify the effective start date of July 5, 2021, for the new CFO.
- Confirm the currency conversion of the NIS 37,500 monthly salary to USD for total compensation analysis.
- Monitor future filings for the specific terms of the discretionary bonus and equity grant packages.
- Review the Company's most recent 10-K or 10-Q for actual financial performance data, as this 8-K contains none.